Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: NPT, SVY

AACC Lays Out Path to Advancing Patient Care Through Artificial Intelligence and Big Data


WASHINGTON, July 29, 2021 /PRNewswire/ -- Artificial intelligence (AI) and data analytics are key to making personalized medicine a reality, but many hurdles still need to be overcome before these technologies can reach their full potential in the healthcare realm. Today, AACC released a position statement urging federal agencies to implement policies that will enable the healthcare community to fully harness the power of AI and data analytics to transform patient care.

Read the position statement here: https://www.aacc.org/advocacy-and-outreach/position-statements/2021/data-analytics-and-laboratory-medicine

Clinical laboratory tests play a vital role in diagnosing and managing a broad range of conditions, from COVID-19 and the flu to diabetes and cancer, and in the process, these tests generate a wealth of data on patients. With the emergence of AI technology, it's now possible for clinical labs to analyze this data with greater precision and to mine it for new insights into patient physiology and population health. These insights, in turn, could lead to the development of the personalized treatments that are needed to drive healthcare forward. Many challenges still need to be solved, though, before clinical labs and the medical community at large can widely implement AI and data analytics in a way that is both effective and equitable. These challenges include combating financial incentives that encourage healthcare organizations to withhold their data for proprietary uses, as well as inconsistencies in the way that lab data is collected that make it difficult for institutions to exchange data.

To pave the way for the broad use of AI and data analytics, first and foremost AACC calls on federal agencies to provide resources and incentives that encourage healthcare providers to develop and adopt these technologies. The federal government should also increase funding for CDC's ongoing effort to harmonize laboratory test results, which is vital to improving the interoperability of lab data (i.e., the ability to exchange data consistently and accurately). In tandem with this, federal policy should prioritize payment reforms that promote secure, ethical, and reciprocal data sharing among health systems and providers. Additionally, AACC recommends that the clinical laboratory and healthcare communities collaborate to develop and promulgate standardized rules for data collection, sharing, and utilization.

"AACC strongly encourages policymakers and the healthcare community to promote the adoption of AI and data analytics tools, to incentivize data sharing between organizations, and to simplify data collection by supporting data interoperability," said AACC President Dr. David G. Grenache. "Together, these measures will enable the medical community to leverage the vast amounts of data generated by clinical laboratories, which is a crucial step toward developing new interventions that will improve the quality of patient care and lower healthcare costs."

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Christine DeLong
AACC
Senior Manager, Communications & PR
(p) 202.835.8722
[email protected]

Molly Polen
AACC
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
[email protected] 

SOURCE AACC


These press releases may also interest you

at 16:13
Total revenues were $2.36 billion, above the midpoint of the guidance range of $2.30 billion +/- $125 million;GAAP diluted EPS attributable to KLA was $4.43 and non-GAAP diluted EPS attributable to KLA was $5.26, both of which were near the upper end...

at 16:10
Boyd Gaming Corporation today reported financial results for the first quarter ended March 31, 2024. Keith Smith, President and Chief Executive Officer of Boyd Gaming, said: "After a record 2023, the first quarter of 2024 was a challenging start...

at 16:10
Finer detail and even greater precision are coming to Stratasys' SAFtm technology. Today, Stratasys announced its new SAFtm HighDef Printing capabilities and the launch of the H350tm printer, Version 1.5 (V.1.5) to expand SAF adoption with...

at 16:10
Carlisle Companies Incorporated today announced its first quarter 2024 financial results. Diluted EPS of $3.52 and adj. EPS of $3.72, an increase of 85% YoY Revenue of $1.1 billion, an increase of 23% YoY Operating margin of 20.5% and adj....

at 16:05
Data I/O Corporation , the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, today announced financial results for the first quarter ended March 31, 2024. First Quarter...

at 16:05
SkyWest, Inc. ("SkyWest") today reported financial and operating results for Q1 2024, including net income of $60 million, or $1.45 per diluted share, compared to net loss of $22 million, or $0.45 loss per share, for Q1 2023. Commenting on the...



News published on and distributed by: